Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition

Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome. The post Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition appeared first on MedCity News.

Community Pharmacies Fill Critical Healthcare Gaps in Rural Areas — Here’s How We Can Empower and Support Them

We need to equip pharmacists with technology that can help them to make impactful clinical interventions in the pharmacy and reimburse them for these services, which would help to address the provider shortage. The post Community Pharmacies Fill Critical Healthcare Gaps in Rural Areas — Here’s How We Can Empower and Support Them appeared first…

Precision Psychiatry is Possible — Especially if We Use Evidence-based Neural Measures to Drive Better Mental Health Treatment and Outcomes

By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders. The post Precision Psychiatry is Possible — Especially if We Use Evidence-based Neural Measures to Drive Better Mental Health Treatment and Outcomes appeared first on MedCity News.

Daily Digest: Moody’s RMS pegs Helene and Milton losses, BP Marsh backs energy MGA, Ransomware claims severity surges

Catch up on the essential news and analysis from the Insurance Day experts       Related Stories Singapore to block Allianz’s acquisition of majority stake in Income Insurance Daily Digest: Combined hurricane losses could reach $55bn, BP Marsh backs energy MGA, Ransomware claims severity surges in H1 Arch Capital chief executive Grandisson retires